

## BIOVICA AND EISAI INC. ENTER INTO LAB SERVICES AGREEMENT TO ASSESS DIVITUM™ AS A TOOL FOR EFFICACY EVALUATION IN CANCER MODELS

**Biovica and Eisai Inc. have entered into a lab services agreement to analyze DiviTum™, an assay measuring serum thymidine kinase, for improved drug evaluation in animal cancer models.**

In a preclinical setting at Eisai's Andover innovative Medicine's (AiM) Institute, Biovica's non-invasive DiviTum™ technology will be used to test for evidence of tumor growth rate and correlation to tumor volume change. The objective is to investigate DiviTum™ as a tool for early evidence of drug efficacy that later can be transferred to be studied in humans and clinical studies, since DiviTum™ is able to measure enzymes strongly connected with the DNA-synthesis and cell proliferation rate.

*"We look forward to working with Eisai, a company which develops important cancer drugs and has a substantial oncology pipeline. In this project we want to demonstrate the preclinical utility and unique information that DiviTum™ can provide to pharmaceutical companies developing novel oncology drugs," said Biovica CEO Anders Rylander. "This aligns with our strategy to present DiviTum™ as a valuable tool in the early setting, in order to provide data that may be of great use in future clinical development and for the benefit of cancer patients."*

Eisai's AiM Institute is a dedicated R&D innovation unit in Andover, Mass., which consists of 90 scientists focused delivering novel targeted medicines, discovered and validated by human genetics and related sources to patients. To learn more about Eisai AiM, please visit [www.EisaiUS-Aim.com](http://www.EisaiUS-Aim.com).

*"This work will allow us to examine whether DiviTum™ can give us early signals of efficacy in blood collected from our pre-clinical animal models. If successful, this information could support future development of targeted medicines and translate into clinical utility,"* said Mark Matijevic, Associate Director, Translational Biomedicine, Eisai AiM Institute.

### EISAI Inc.

At Eisai Inc., human health care (hhc) is our goal. We give our first thought to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.

Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit [www.eisai.com/US](http://www.eisai.com/US).

### Eisai Media Inquiries

Patricia Council  
+1 201 746 2139

### Eisai Investor Inquiries

Ivor Macleod  
+1 201 746 2660

### BIOVICA AND DIVITUM™

Biovica is a bio-diagnostic company focused on providing improved diagnostics, predictive data and monitoring of cancer patient under treatment. Biovica has developed DiviTum™, a highly sensitive assay for measuring cell proliferation. Since one of the most fundamental characteristics of cancer is uncontrolled and increased cell growth, DiviTum™ enables valuable prediction capability and monitoring of compounds regulating cell proliferation and the cell cycle. Biovica is ISO 13485 certified for Quality Management Systems and DiviTum™ is CE labeled and MPA registered.

See also [www.biovica.com](http://www.biovica.com)

### Biovica Media Inquiries

Anders Rylander, CEO Biovica  
Mobile phone: +46 (0) 761 61 21 90  
e-mail: [anders.rylander@biovica.com](mailto:anders.rylander@biovica.com)